Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?
Author:
- 31 August 2009
- journal article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 34 (3) , 529-530
Abstract
In the present issue of the European Respiratory Journal, Lavelle et al. 2 from Dublin, Ireland report on two perturbing cases of severe liver toxicity that developed 3 and 4 months, respectively, after sitaxentan therapy had been initiated. These patients showed severe liver dysfunction, with markedly elevated bilirubin levels >300 μmol·L−1 and elevated prothrombin times. In both patients, liver biopsies showed extensive hepatocellular damage and infiltrates of eosinophils and lymphocytes. As in the first case, liver function deteriorated for several weeks after discontinuation of sitaxentan. Corticosteroid therapy was not attempted. One of these patients recovered slowly, the other, however, died from pneumonia ∼2 months after withdrawal of sitaxentan. At that time, bilirubin levels were still >200 μmol·L−1, indicating persistent liver dysfunction, which may have contributed to the fatal outcome.Keywords
This publication has 9 references indexed in Scilit:
- Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertensionEuropean Respiratory Journal, 2009
- Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy: Fig. 1—European Respiratory Journal, 2009
- Endothelin receptor antagonists in pulmonary arterial hypertensionEuropean Respiratory Journal, 2008
- Results of European post-marketing surveillance of bosentan in pulmonary hypertensionEuropean Respiratory Journal, 2007
- Sitaxsentan Treatment for Patients With Pulmonary Arterial Hypertension Discontinuing BosentanThe Journal of Heart and Lung Transplantation, 2007
- Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist SitaxsentanJACC, 2006
- Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failureJournal of Hepatology, 2004
- Clinical Efficacy of Sitaxsentan, an Endothelin-A Receptor Antagonist, in Patients With Pulmonary Arterial HypertensionChest, 2002
- The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactionsClinical Pharmacology & Therapeutics, 2001